Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGUE-26 catheter-directed thrombolysis in intermediate-high risk acute pulmonary embolism
2024-516144-25-00Phase 4Authorised
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms), sponsored by Faculty Hospital Kralovske Vinohrady. Primary endpoints: All-cause mortality within 7 days, Pulmonary embolism recurrence within 7 days and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2024-516144-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516144-25-00.